Contraception · 2025
Contraceptive market, utilization patterns, and coverage in Colombia (2020-2025).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dávila Fabian, Cala-Vitery Favio
Аннотация
OBJECTIVE: We analyzed contraceptive market dynamics in Colombia by comparing pricing, utilization patterns, and population coverage between insurance-covered and out-of-pocket purchase groups to identify barriers to equitable reproductive health access.
STUDY DESIGN: We conducted a retrospective analysis (2020-2025) using Colombia's national pharmaceutical databases (SISMED, BDUA, CUM-INVIMA). We examined pricing (maximum cost per minimum dispensable unit), annual market values, utilization (defined daily dose per 1000 women-years), and population coverage (couple years of protection) by comparing insurance-covered versus out-of-pocket purchase groups.
RESULTS: Hormonal IUDs showed minimal price variation ($144.00 insurance versus $145.11 out-of-pocket). Injectable contraceptives achieved 72% price reductions while emergency contraception maintained substantial price disparities with out-of-pocket prices up to 25 times higher than insurance-covered prices. Out-of-pocket purchase groups accumulated 64-70% of the total annual market value ($29.9-48.6M) through oral contraceptives and emergency contraception. Insurance-covered purchase groups accounted for 31-36% ($17.0-29.0M), specializing in subdermal implants. Out-of-pocket groups dominated total contraceptive utilization (78-86% of defined daily doses) versus 14-22% for insurance-covered groups. National contraceptive protection increased from 28% (2020) to 37% (2022), then stabilized at 33% (2023-2024). Insurance-covered groups reached only eight to10% of the population despite providing highly effective methods.
CONCLUSIONS: Colombia's contraceptive market demonstrates persistent segmentation and structural barriers beyond pricing. Policy interventions require strengthening insurance-covered service delivery capacity and implementing targeted out-of-pocket sector reforms to ensure equitable access.
IMPLICATIONS: Policy makers should strengthen institutional capacity for long-acting reversible methods while ensuring commercial equity for comprehensive contraceptive access.
STUDY DESIGN: We conducted a retrospective analysis (2020-2025) using Colombia's national pharmaceutical databases (SISMED, BDUA, CUM-INVIMA). We examined pricing (maximum cost per minimum dispensable unit), annual market values, utilization (defined daily dose per 1000 women-years), and population coverage (couple years of protection) by comparing insurance-covered versus out-of-pocket purchase groups.
RESULTS: Hormonal IUDs showed minimal price variation ($144.00 insurance versus $145.11 out-of-pocket). Injectable contraceptives achieved 72% price reductions while emergency contraception maintained substantial price disparities with out-of-pocket prices up to 25 times higher than insurance-covered prices. Out-of-pocket purchase groups accumulated 64-70% of the total annual market value ($29.9-48.6M) through oral contraceptives and emergency contraception. Insurance-covered purchase groups accounted for 31-36% ($17.0-29.0M), specializing in subdermal implants. Out-of-pocket groups dominated total contraceptive utilization (78-86% of defined daily doses) versus 14-22% for insurance-covered groups. National contraceptive protection increased from 28% (2020) to 37% (2022), then stabilized at 33% (2023-2024). Insurance-covered groups reached only eight to10% of the population despite providing highly effective methods.
CONCLUSIONS: Colombia's contraceptive market demonstrates persistent segmentation and structural barriers beyond pricing. Policy interventions require strengthening insurance-covered service delivery capacity and implementing targeted out-of-pocket sector reforms to ensure equitable access.
IMPLICATIONS: Policy makers should strengthen institutional capacity for long-acting reversible methods while ensuring commercial equity for comprehensive contraceptive access.